FDA approves cord blood stem cell product for blood cancer patients
The U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic cord blood-based cell therapy, to cut the risk of infection in patients with blood cancer following a myeloablative ...
Apr 24, 2023
0
0